Efanesoctocog Alfa on Fast Track for Hemophilia A

Efanesoctocog Alfa on Fast Track for Hemophilia A

287098

Efanesoctocog Alfa on Fast Track for Hemophilia A

The U.S. Food and Drug Administration (FDA) has granted fast track designation to efanesoctocog alfa, an investigational factor VIII (FVIII) replacement therapy for treating hemophilia A, Sanofi, one of the therapy’s developers, announced in a press release. This designation is given to accelerate the development and review of medications intended to treat serious or life-threatening conditions for which there is a high unmet clinical need. Therapies that receive fast track may be eligible for accelerated approval…

You must be logged in to read/download the full post.